Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Bull's Eye: Buy Essar Oil, Castrol, UPL, sell India Cements

      Avinnash Gorakssakar of Precision Investment Services advises buying Natco Pharma with a target of Rs 2525.

    • Buy Glenmark, has potential to reach higher levels: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Glenmark Pharma as the stock has a lot of potential to reach higher levels.

    • Buy Glenmark Pharma 1060 Call, sell 1120 Call: VK Sharma

      According to VK Sharma of HDFC Securities, one can buy Glenmark Pharma 1060 Call and sell 1120 Call.

    • Prefer midcap pharma space: Hemindra Hazari

      Hemindra Hazari, independent market expert is of the view that Midcap pharma is going to be a better bet because large cap pharma.

    • Investors should consider buying Glenmark Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one should consider buying Glenmark Pharma.

    • Buy L&T on correction, look at Tata Motors: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher recommends buying Larsen & Toubro on correction and feels that one can look at Tata Motors.

    • Overweight on pharma, private sector banks: Dipan Mehta

      Dipan Mehta - member at BSE & NSE maintains overweight position on pharma as well as private sector banks.

    • Like pharma sector, prefer Lupin: Jeff Chowdhry

      Jeff Chowdhry, senior EM Fund Manager at LGM likes the pharma sector and prefer Lupin.

    • Prefer Glenmark Pharma, Cadila Healthcare: Anu Jain

      Anu Jain of IIFL Private Wealth Management prefers Glenmark Pharma and Cadila Healthcare from the pharma space.

    • Aurobindo Pharma, Glenmark Pharma top picks: R Sreesankar

      According to R Sreesankar, head - institutional equities at Prabhudas Lilladher, Aurobindo Pharma and Glenmark Pharma are the top picks.

    • Glenmark Pharma top pick, says R Sreesankar

      R Sreesankar, Head-Institutional Equities at Prabhudas Lilladher is of the view that Glenmark Pharma is the top pick.

    • Pick Persistent Systems, YES Bank, Glenmark: R Sreesankar

      R Sreesankar, Head-Institutional Equities at Prabhudas Lilladher is of the view that YES Bank, Glenmark Pharma, Cummins India, Ashok Leyland and Ashoka Buildcon, JK Lakshmi Cement and Persistent Systems are the top picks in the midacp space.

    • Sell Glenmark Pharma, says Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may sell Glenmark Pharma.

    • Exit Natco Pharma, buy Sun Pharma, Glenmark: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends exiting Natco Pharma and advises buying Glenmark Pharma, Dr Reddy's Laboratories and Sun Pharma at lower levels.

    • Buy Glenmark Pharma on dips, may hit Rs 1040: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one can buy Glenmark Pharma on dips as the stock may touch Rs 1040.

    • Buy Glenmark Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma.

    • Glenmark top pick, prefer Ashok Leyland: Ajay Bodke

      According to Ajay Bodke of Prabhudas Lilladher, Glenmark Pharma is the top pick from the pharma space and favours Ashok Leyland over Tata Motors as an investment revival theme.

    • Sell Arvind, buy Glenmark Pharma: Manas Jaiswal

      According to Manas Jaiswal of manasjaiswal.com, one may sell Arvind and buy Glenmark Pharma.

    • Glenmark Pharma can retest Rs 915-920: Hemant Thukral

      Hemant Thukral of Aditya Birla Money feels that Glenmark Pharma can retest Rs 915-920.

    • Glenmark Pharma top pick, says Amisha Vora

      Amisha Vora of Prabhudas Lilladher is of the view that Glenmark Pharma is the top pick.

    • Prefer Glenmark Pharma: Anand Tandon

      Anand Tandon, Market Expert is of the view that one may prefer Glenmark Pharma.

    • Buy Aurobindo Pharma, Lupin: Vishal Malkan

      Vishal Malkan of malkansview.com suggests buying Aurobindo Pharma and Lupin.

    • Top buzzing midcap stocks to trade on June 1

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Maruti Suzuki, Eicher Motor, BEML, HCC, Sun Pharma, IL&FS Engg, Hathway Cables, Glenmark Pharma & ITDC.

    • Glenmark, Dr Reddy's top picks: R Sreesankar

      R Sreesankar, Head-Institutional Equities at Prabhudas Lilladher is of the view that Glenmark Pharma, Dr Reddy's Laboratories and Aurobindo Pharma are the top picks from the pharma space.

    • Buy Glenmark Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Glenmark Pharma and hold the stock for a few days.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347